XORTX Therapeutics Inc. (XRTX)
| Previous close | 2.9400 |
| Open | 2.9600 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 2.8500 - 2.9999 |
| 52-week range | 1.9800 - 67.7160 |
| Volume | |
| Avg. volume | 49,737 |
| Market cap | 8.411M |
| Beta (5Y monthly) | -0.15 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.6000 |
| Earnings date | 15 May 2024 - 20 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 12.21 |
GlobeNewswireXORTX Announces Publication of Key Research in ADPKD
CALGARY, Alberta, April 22, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA WKN: A3UNZ), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce a research paper titled “Raising serum uric acid with a uricase inhibitor worsens PKD in rat and mouse models" has been accepted for publication in the peer-reviewed American Journal of Phys
- GlobeNewswire
XORTX Welcomes New Member to the Board of Directors
CALGARY, Alberta, April 08, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA WKN: A3UNZ), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, welcomes Abigail Jenkins, a biotech industry veteran with deep experience with the commercialization of therapies for renal and cardiovascular disease, to its Board of Directors. Abigail “Abbey” L. Jenkins, M.S.,
- GlobeNewswire
XORTX Announces Participation in Spring 2024 Investor Conferences
CALGARY, Alberta, April 08, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA WKN: A3UNZ), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces that Dr. Allen Davidoff, CEO, is scheduled to participate in the following Spring 2024 investor and life sciences investment conferences: LD Micro Invitational XIV in New York, April 8-9Management will d
